Vimseltinib — Drug Monograph

Brand names: Romvimza

Drug class: Tyrosine Kinase Inhibitor

Mechanism of Action

Oral, highly selective switch-control inhibitor of the colony-stimulating factor 1 receptor (CSF1R). By locking CSF1R in an inactive conformation, vimseltinib blocks CSF1/IL-34 signaling that drives the proliferation of neoplastic and reactive synovial macrophages in tenosynovial giant cell tumor (TGCT). Its switch-control design confers high kinase selectivity, sparing closely related kinases (KIT, PDGFR, FLT3) and thereby avoiding much of the off-target toxicity seen with earlier multikinase CSF1R inhibitors.

FDA Indications

• Symptomatic tenosynovial giant cell tumor (TGCT) in adults for which surgical resection would cause worsening functional limitation or severe morbidity (approved February 14, 2025; MOTION Phase 3: ORR 40% vs 0% with placebo at week 25)

Common Side Effects

• Periorbital and peripheral edema
• Fatigue
• Increased AST/ALT
• Increased creatine kinase (CK)
• Rash
• Pruritus
• Headache
• Increased cholesterol

Clinical Pearl

Vimseltinib is a highly selective, twice-weekly oral CSF1R inhibitor for symptomatic TGCT that is not amenable to surgery. Compared with pexidartinib, it lacks a boxed hepatotoxicity warning and a REMS requirement, making it an easier-to-manage systemic option for this rare, locally aggressive but benign joint tumor.

Related Therapies & Mechanisms

• Afatinib (Gilotrif) — Tyrosine Kinase Inhibitor
• Alectinib (Alecensa) — Tyrosine Kinase Inhibitor
• Alpelisib (Piqray) — Tyrosine Kinase Inhibitor
• Asciminib (Scemblix) — Tyrosine Kinase Inhibitor